Covalon Technologies (Covalon Technologies) ROE % Adjusted to Book Value : -13.03% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Covalon Technologies ROE % Adjusted to Book Value?

Covalon Technologies's ROE % for the quarter that ended in Dec. 2023 was -18.77%. Covalon Technologies's PB Ratio for the quarter that ended in Dec. 2023 was 1.44. Covalon Technologies's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -13.03%.

Covalon Technologies ROE % Adjusted to Book Value Historical Data

The historical data trend for Covalon Technologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Covalon Technologies ROE % Adjusted to Book Value Chart

Covalon Technologies Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-16.71

-16.26

52.36

-12.76

-11.43

Covalon Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-2.63	-5.28	-4.64	-31.76	-13.03

Competitive Comparison of Covalon Technologies's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Covalon Technologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Covalon Technologies's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Covalon Technologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Covalon Technologies's ROE % Adjusted to Book Value falls into.

Covalon Technologies ROE % Adjusted to Book Value Calculation

Covalon Technologies's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-20.57%	/	1.80
	=	-11.43%

Covalon Technologies's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-18.77%	/	1.44
	=	-13.03%

Covalon Technologies ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Covalon Technologies's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Covalon Technologies (Covalon Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Covalon Technologies Ltd (OTCPK:CVALF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

COV:Canada

Address

1660 Tech Avenue, Unit 5, Mississauga, ON, CAN, L4W 5S7

Website

https://www.covalon.com

Covalon Technologies Ltd is principally engaged in the business of developing, licensing, and selling medical technologies. The company develops advanced wound care line which is designed for the treatment of a wide range of wounds; and infection prevention products such as MediClear PreOp which is a breathable, transparent, self-adhesive silicone barrier film that conforms to the contours of the body. It also develops perioperative care products. The company generates its revenue through development contracts, licensing agreements, and distribution contracts, and sales.